NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky is investigating potential claims on behalf of purchasers of Atossa Genetics, Inc. (Atossa or the Company) (ATOS) securities concerning possible violations of securities laws.

For more information, click here: http://zlk.9nl.com/atossa-genetics-atos.

On October 4, 2013, Atossa announced a voluntary recall (the recall) of its ForeCYTE Breast Health Test Mammary Aspiration Specimen Cytology Test (MASCT), including the recall of the MASCT System Kit and Patient Sample Kit. The recall commenced to address concerns raised in a February 2013 warning letter issued by the U.S. Food and Drug Administration (the FDA), in which the FDA raised concerns regarding the current instructions for use (IFU), certain promotional claims used to market these devices, and regarding the need for FDA clearance for certain changes made to the Nipple Aspirate Fluid (NAF) specimen collection process identified in the current IFU.

If you own Atossa stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/atossa-genetics-atos.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

See original here:
ATOSSA GENETICS, INC. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Claims ...

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Good Start Genetics, Inc.,an innovative molecular diagnostics company harnessing a powerful, proprietary next-generation DNA sequencing (NGS) capability, today announced that new data further supporting their robust platform validation and the clinical value of the GoodStart SelectTM carrier screening test will be presented during two poster sessions at the 2013 American Society for Reproductive Medicine Annual Meeting taking place October 12 17 in Boston.

The schedule for presentations by Good Start Genetics is as follows:

Date & Time: Tuesday, October 15, 2013 from 7:00 8:45 a.m. Title: A RIGOROUS PROCESS FOR SELECTING AN OPTIMAL MUTATION SET FOR POPULATION-BASED CARRIER SCREENING Program Number: P018 Session ID: P-149

Date & Time: Thursday, October 17, 2013 from 7:00 8:45 a.m. Title: CARRIER SCREENING OF 8,500 IVF PATIENTS UTILIZING NEXT GENERATION DNA SEQUENCING DETECTS COMMON, RARE AND OTHERWISE UNDETECTABLE MUTATIONS ACROSS SOCIETY-RECOMMENDED DISEASES Program Number: P048 Session ID: P-1151

About GoodStart Select

GoodStart Select is Good Start Genetics menu of carrier screening tests that, for diseases such as cystic fibrosis, detects many more disease-causing mutations than any other routine carrier screening test, regardless of patient ethnicity. After years of development and rigorous validation, Good Start Genetics has harnessed the power of its sophisticated technologies, including next-generation DNA sequencing (NGS), to provide highly accurate and actionable tests resulting in higher mutation detection rates and fewer missed carriers. Good Start offers genetic screening tests for all disorders recommended by the American Congress of Obstetricians and Gynecologists (ACOG), the American College of Medical Genetics and Genomics (ACMG), and leading Jewish advocacy groups.

To support the companys gold standard genetic screening capabilities, Good Start has a dedicated team of customer care specialists, board certified medical geneticists and genetic counselors who provide step-by-step support, from test selection through results, analysis and reporting. For these reasons, reproductive health specialists and their patients can have the highest degree of confidence in their genetic carrier screening results.

About Good Start Genetics, Inc.

Good Start Genetics is an innovative molecular diagnostics company harnessing a powerful, proprietary next-generation DNA sequencing (NGS) capability combined with other technologies to deliver best-in-class tests for routine genetic screening. Through its GoodStart Select offering, the company provides the most comprehensive and clinically actionable set of tests for known and novel mutations that cause inherited diseases. Good Starts NGS capabilities can be applied to multiple disease areas, including pre-conception carrier screening in the in-vitro fertilization setting. For more information, please visit http://www.goodstartgenetics.com.

Originally posted here:
Good Start Genetics to Present Clinical Data at 2013 American Society for Reproductive Medicine Annual Meeting

Recommendation and review posted by Bethany Smith

RUTHERFORD, N.J., Oct. 8, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, today announced its vice president of R&D, Jane Houldsworth, Ph.D., will provide the opening keynote presentation for the "Realizing the Potential of Precision Medicine" conference on October 9, 2013 at 1:00 pm ET.

"The use of genetic information to improve diagnosis, treatment and patient outcomes is the very foundation of precision medicine," stated Panna Sharma, CEO of CGI. "This conference brings together key industry thought leaders to provide attendees with insights on how to apply precision medicine in the clinical setting. Participating companies include major players in genetics, such as Illumina and Luminex. Other participants include Weill Cornell Medical College, New-York Presbyterian Hospital and other key institutions that serve the needs of oncology patients. For CGI to have the honor of opening this conference is a testament to our leadership position in the rapidly evolving field of precision medicine."

Dr. Houldsworth's keynote "From Vision to Reality, the Cancer Genetics Complete Experience," will use CGI's Complete Programs(TM) as a case study to strategize the introduction and successful licensure of molecular and biomarker based diagnostic testing. Her keynote will also address preparation for constant upgrading and expansion to include novel findings and methodological advances.

Dr. Houldsworth has over 20 years of experience in translational research and has published more than 50 peer-reviewed papers and 15 chapters. Since her joining CGI in 2007, Dr. Houldsworth has successfully led the clinical validations and licensures of CGI's proprietary products including MatBA(R) and UroGenRA(TM).

The conference, "Realizing the Potential of Precision Medicine," will take place at the AMA Conference Center in New York City, October 9 to October 11, 2013. Registration can be done at http://goo.gl/aHOxff. The conference is suited for executives and health care professionals representing academic medical centers, community hospitals, and hospital and health networks, and the event should provide networking and deal-making opportunities.

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers. These cancers include hematological, urogenital and HPV-associated cancers. The Company's comprehensive range of oncology-focused tests and laboratory services provide critical genomic information to healthcare professionals, cancer centers, and biopharma companies. Through its CLIA certified and CAP accredited state-of-the-art reference lab, Cancer Genetics services some of the most prestigious medical institutions in the world and has strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see http://www.cancergenetics.com.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended June 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

Read this article:
Cancer Genetics, Inc. Will Open Precision Medicine Conference With Keynote Presentation

Recommendation and review posted by Bethany Smith

Public release date: 8-Oct-2013 [ | E-mail | Share ]

Contact: Karen Mallet km463@georgetown.edu Georgetown University Medical Center

WASHINGTON A team of researchers at Georgetown University Medical Center (GUMC) has found that loss of an anti-aging gene induces retinal degeneration in mice and might contribute to age-related macular degeneration, the major cause of blindness in the elderly.

In the Oct. 9 issue of the Journal of Neuroscience, the scientists demonstrated a key role for the aging-suppressor gene Klotho in maintaining the health of the mouse and human retina. They say that in their animal studies, loss of Klotho expression leads to characteristics observed in both kinds of macular degeneration wet and dry seen in humans.

Klotho, a hormone that is synthesized and secreted by some organs and tissues, is being studied worldwide for its anti-aging properties. A Japanese researcher discovered 15 years ago that when Klotho is mutated, a mouse that should live two years survives for only two months. Transgenic mice that overexpress the Klotho gene have a longer-than-expected lifespan.

"We found four important functions Klotho provides in the human retina, which leads us to believe that the gene is crucial to the health of this light sensitive tissue," says the study's senior investigator, Nady Golestaneh, PhD, assistant professor of ophthalmology, neurology, biochemistry and molecular & cellular biology at GUMC.

They found that Klotho increases the activity of genes that synthesize the light absorbing visual pigments in the retinal cells. Klotho also increases the expression of genes that protect against the oxidative stress known to damage the retina, and which can lead to dry macular degeneration. Klotho inhibits the vascular endothelial growth factor and therefore, might play an important role in inhibiting the overgrowth of blood vessels in the eye, a major cause of wet macular degeneration.

Klotho also regulates phagocytosis of the outer segment of photoreceptors in the retina. This process allows the photoreceptors to renew themselves, and if that function is abolished, the photoreceptors degenerate and die causing blindness.

"For these reasons, we believe Klotho might be an interesting therapeutic target for age-related macular degeneration," Golestaneh says. "Gene therapy or cell therapy might be able to induce new expression of Klotho in the aging retina."

But she adds that before these strategies can be tested, research that quantifies the decline of Klotho expression in human eyes, and directly links this dysfunction to macular degeneration, must be undertaken.

See original here:
Loss of anti-aging gene possible culprit in age-related macular degeneration

Recommendation and review posted by Bethany Smith

Purtier Placenta Live stem Cell Therapy Miracle - Mr Wilson Grandma is healthy now after 8 months
This video is from YouTube Channel-wilsonho ho. In his YouTube Wilson never mentions much. Just a short message, My grandmother is healthy now after 8months ...

By: Purtier Placenta Singapore Original

More:
Purtier Placenta Live stem Cell Therapy Miracle - Mr Wilson Grandma is healthy now after 8 months - Video

Recommendation and review posted by simmons

Brad discusses his combination cell therapy for his arthritic knee
20 months after his bone marrow aspirate concentrate and adipose injection into his arthritic knee, Brad discusses his result. Dr Adelson practices in Park C...

By: Harry Adelson

Go here to see the original:
Brad discusses his combination cell therapy for his arthritic knee - Video

Recommendation and review posted by Bethany Smith

Cell Therapy - Breast Cancer
For More Information Visit: http://www.progenacell.com/

By: Charles Studios

Read more here:
Cell Therapy - Breast Cancer - Video

Recommendation and review posted by Bethany Smith

Cell Therapy - Can You Be Cancer Free?
For More Information Visit: http://www.progenacell.com/

By: Charles Studios

Continued here:
Cell Therapy - Can You Be Cancer Free? - Video

Recommendation and review posted by Bethany Smith

Cell Therapy - Dormant Cells
For More Information Visit: http://www.progenacell.com/

By: Charles Studios

More here:
Cell Therapy - Dormant Cells - Video

Recommendation and review posted by Bethany Smith

Cell Therapy - Prostate Cancer
For More Information Visit: http://www.progenacell.com/

By: Charles Studios

Here is the original post:
Cell Therapy - Prostate Cancer - Video

Recommendation and review posted by Bethany Smith

Cell Therapy - Sleeper Cell
For More Information Visit: http://www.progenacell.com/

By: Charles Studios

Continued here:
Cell Therapy - Sleeper Cell - Video

Recommendation and review posted by Bethany Smith

What is Advanced Swiss Cell Therapy?

By: Yuvacell

View post:
What is Advanced Swiss Cell Therapy? - Video

Recommendation and review posted by Bethany Smith

Newswise COLUMBUS, Ohio The National Institutes of Health has awarded a $25.4 million grant to The Ohio State University Center for Clinical and Translational Science (CCTS), a collaboration between The Ohio State University and Nationwide Childrens Hospital (NCH) created to accelerate basic science discoveries into life-saving medical advances.

This award is a confirmation that Ohio State has successfully created a strong clinical and translational research environment where basic scientists and clinicians can leverage the resources of a nationally recognized pediatric hospital, Ohio States Wexner Medical Center, seven health science colleges, as well as other resources from one of the largest public universities in the nation, said Charles Lockwood, MD, Dean of the Ohio State University College of Medicine. We find that the barriers to such multidisciplinary research collaboration are virtually non-existent here.

The NIHs endowment is funding of a multi-million dollar Clinical and Translational Science Award (CTSA) that was originally given to the CCTS in 2008. Since then, the Center has helped connect hundreds of researchers across the state of Ohio with the resources needed to discover new techniques and treatments for todays deadliest and costliest diseases including obesity, diabetes, heart disease, cancer, and Alzheimers, as well as a variety of disabling childhood illnesses like muscular dystrophy.

Steven Gabbe, MD, chief executive officer of OSUs Wexner Medical Center, believes one reason that the CCTS program has been successful is that leaders from both Ohio State and Nationwide Childrens Hospital recognize how important translational research and training clinician-scientists is to the evolution of healthcare.

Translational research is critical to our mission of transforming sick care into healthcare, and were committed to creating an environment where discovery fuels innovation in patient care, Gabbe said. The design of the new James Cancer Hospital and Solove Research Institute and Critical Care Center is an excellent example of this. It combines research and education space on every patient care floor, which will accelerate the creation of new diagnostic tools and treatments.

Both the Ohio State and Nationwide Childrens campuses have dedicated substantial resources and infrastructure to grow our translational research capabilities, said John Barnard, MD, President of The Research Institute at Nationwide Childrens . This investment has delivered some major breakthroughs, particularly with gene therapy for some of the most deadly and debilitating muscular diseases. Our partnership is giving us new insights in the continuum of care as children with chronic disease grow into adults , and offering new possibilities for preventing disease altogether.

The CCTS has been also been successful in creating partnerships, infrastructure and programs that drive innovation, training the next generation of scientists, and making the research process more efficient three of the NIHs key goals.

Earlier this year, we signed an historic agreement that includes the two other institutions in the Ohio CTSA network and their partners that centralized our review process, making it dramatically easier for our researchers to collaborate with seven different facilities across the state, noted Rebecca Jackson, MD, director of the Ohio State CCTS. We also joined six other Midwest CTSAs to create a regional consortium that minimizes duplication and makes data capture for multi-site studies more standardized and efficient.

The CCTS facilitated the development of a similar network of institutional partners in Appalachia the Appalachian Translational Research Network which is focused on addressing the significant health challenges and disparities specific to Appalachia.

The CCTS has also helped created shared research resources with sustainability in mind. Two of these resources include the Clinical Research Center, a full service research laboratory, and the Laser Capture Microdissection Core, a lab that collects precise, nano-sized tissue samples. The services were originally fully-funded by the CCTS, but by building them around a sustainable business model, both are close to being self-sufficient operations and are used by researchers across campus.

See the original post here:
$25.4 Million Awarded to Ohio State to Continue Critical "Bench to Bedside" Translational Research

Recommendation and review posted by Bethany Smith

Topics: skin, skin cancer, sun, sunscreen

NEXT time your kids complain about putting on sunscreen, tell them this: Sunscreen shields a superhero gene that protects them from getting cancer.

It is widely accepted that sunscreen stops you from getting burnt but to date there has been academic debate about the effectiveness of sunscreen in preventing skin cancers.

Now QUT has undertaken a world-first human study to assess the impact of sunscreen at the molecular level.

Researchers found sunscreen provides 100 per cent protection against all three forms of skin cancer: BCC (basal cell carcinoma); SCC (squamous cell carcinoma); and malignant melanoma.

Lead researcher Dr Elke Hacker, from QUT's AusSun Research Lab, said sunscreen not only provided 100 per cent protection against the damage that can lead to skin cancer but it shielded the important p53 gene, a gene that works to prevent cancer.

"As soon as our skin becomes sun damaged, the p53 gene goes to work repairing that damage and thereby preventing skin cancer occurring.

"But over time if skin is burnt regularly the p53 gene mutates and can no longer do the job it was intended for - it no longer repairs sun damaged skin and without this protection skin cancers are far more likely to occur."

The study, published in the Pigment Cell & Melanoma Research journal, looked at the impact of sunlight on human skin, both with and without sunscreen, and found no evidence of UV-induced skin damage when proper application of sunscreen (SPF30+) had been applied to exposed area.

"Melanoma is the most lethal form of skin cancer with research showing damage of melanocytes - the pigment-producing cells of the skin - after sun exposure plays a role in the development of skin cancer," Dr Hacker said.

Here is the original post:
Sunscreen not only saves skin but 'superhero' within

Recommendation and review posted by Bethany Smith

CHICAGO -- Over the past 16 years, biotechnology has helped Ron Moore grow crops that could survive drought, produce higher-quality grain to feed his livestock and yield sweet corn so plentiful his family has donated extras to the church and local food pantry.

"People have said it's the best sweet corn they've ever eaten," said Moore, 57, whose family farms a few thousand acres near the western Illinois community of Roseville.

But the same scientific advances that have so greatly altered the agriculture industry also have made some consumers nervous about what they are putting in their bodies and what long-term effects it could have.

Now that battle has now come to Moore's home state.

Illinois Sen. David Koehler, a Democrat from Peoria, says those concerns are behind legislation he proposed that would require the labeling of food produced with genetic engineering - often called "GMOs," or genetically modified organisms. Koehler, chairman of the House Agriculture Committee, convened a panel of lawmakers for three hearings on the bill over the summer to try to educate the public and the committee on the issue.

Koehler's bill would require farmers and manufacturers to label any food that's available for retail sale in Illinois and that contains more than 1 percent of genetically engineered ingredients. The front or back of the package must clearly state "Produced with Genetic Engineering" or "Partially Produced with Genetic Engineering." The law would be enforced by the Department of Public Health, and producers could be fined for not properly labeling their products.

"For me it's a consumer transparency issue," Koehler said. "Do consumers have a right to know? I obviously believe they do."

GMOs are plants whose DNA has been manipulated in a lab to resist drought, disease and insects and to increase yields. The European Union largely bans them, but most of the corn, soybean, cotton and sugar beets cultivated in the U.S. today contain plants that were genetically modified. They are particularly common in animal feed and processed foods.

More than 60 countries have GMO labeling laws, according to the Center for Food Safety, a non-profit advocacy group. As efforts to pass a federal law in the U.S. haven't gained much traction, supporters have turned to state legislatures. The Center for Food Safety says labeling measures currently are pending in more than two dozen states. Only two - Maine and Connecticut - have approved them.

Advocates say Illinois is a key piece of the state-by-state approach because it's the nation's fifth most populous state and one of the biggest agricultural producers.

Continued here:
Labeling bill raises modified food debate in Illinois

Recommendation and review posted by Bethany Smith

Adapting microbes that dramatically increase crop yields while reducing demand for fertilizers and pesticides through selective breeding or genetic engineering could be cheaper and more flexible than genetically modifying plants themselves, says an author of a report.

Microbes, such as beneficial bacteria, fungi and viruses, could be produced locally for smallholder farmers to significantly improve food security and incomes in developing regions, believes Ann Reid, director of the American Academy of Microbiology and co-author of a report published by the organization last month (27 August).

"Genetic modification of crop plants, which has seen a huge investment, is closed to all but the biggest agricultural companies," she tells SciDev.Net.

"Optimisation of microbes could be done at the level of the local community college and is much more obtainable for a smallholder farmer."

Her comments echo the findings of the report the product of an expert meeting in 2012 which underscored the significant impact microbes could have on food production by increasing crops' absorption of nutrients, resistance to disease and environmental stresses, and even improving flavour.

As well as to accentuate naturally occurring traits such as the secretion of pest-killing toxins or nitrogen-fixation, the modification of microbes is often needed to allow them to be grown in large numbers out of their natural environment.

For example, researchers in Colombia could only produce large quantities of a fungus that improves the nutrient absorption of cassava once they bred a strain of that fungus that was capable of growing on carrot roots.

Recent technological developments in rapid DNA sequencing, imaging and computer modelling can help provide further solutions, as well as building a greater understanding of the complex environment that microbes themselves need to flourish, the report says.

These advances raise the possibility that, within two decades, microbes could increase food production by a fifth and reduce fertiliser demands by the same proportion, it finds.

But to achieve this ambitious goal, the research community must engage in curiosity-driven basic research, develop even cheaper sequencing techniques, and establish a process to move discoveries from the lab to the field, it says.

Read more:
Microbes vs. Genetic Modification

Recommendation and review posted by Bethany Smith

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo News Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? Nightline Fix Beyond the Headline Local Popular Search Keyword News Search

See the article here:
5 Revolutionary Nobel Prizes in Medicine

Recommendation and review posted by Bethany Smith

NEW YORK, Oct. 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Regenerative medicine and Stem cells Partnering Terms and Agreements http://www.reportlinker.com/p01098514/Regenerative-medicine-and-Stem-cells-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the Regenerative medicine and Stem cells partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in regenerative medicine and stem cells deals Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for regenerative medicine and stem cells

The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since 2008 including financial terms where available including over 550 links to online deal records as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following: - What is actually granted by the agreement to the partner company? - What exclusivity is granted? - What are the precise rights granted or optioned? - What is the payment structure for the deal? - How aresalesand payments audited? - What is the deal term? - How are the key terms of the agreement defined? - How are IPRs handled and owned? - Who is responsible for commercialization? - Who is responsible for development, supply, and manufacture? - How is confidentiality and publication managed? - How are disputes to be resolved? - Under what conditions can the deal be terminated? - What happens when there is a change of ownership? - What sublicensing and subcontracting provisions have been agreed? - Which boilerplate clauses does the company insist upon? - Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? - Which jurisdiction does the company insist upon for agreement law?

Go here to read the rest:
Regenerative medicine and Stem cells Partnering Terms and Agreements

Recommendation and review posted by Bethany Smith

SUNDAY, Oct. 6 (HealthDay News) -- Genetics do not play a major role in determining whether people are right- or left-handed, a new study says.

About 10 percent of people worldwide are left-handed, but the reasons why people favor one hand over the other remain unclear.

In an effort to learn more, researchers conducted genetic analyses of nearly 4,000 twins in the United Kingdom, but were unable to find a strong genetic factor in determining handedness.

The study was published recently in the journal Heredity.

Even though they didn't find a strong genetic influence on handedness, the researchers noted that it is widely believed that handedness is not just the result of choice or learning. Therefore, it's likely that genetic factors play at least a minor role in determining handedness.

Another recent study, published in the journal PLoS Genetics, has found that genetics do play a part in handedness, along with environment.

"It is likely that there are many relatively weak genetic factors in handedness, rather than any strong factors, and much bigger studies than our own will be needed to identify such genes unambiguously," John Armour of the University of Nottingham, co-author of the latest study, said in a university news release.

"As a consequence, even if these genes are identified in the future, it is very unlikely that handedness could be usefully predicted by analysis of human DNA," he added.

More information

The Nemours Foundation has more about being left-handed.

The rest is here:
Righty? Lefty? Genes' role still unclear

Recommendation and review posted by Bethany Smith

Cell Therapy - Auto Immune Disease
For More Information Visit: http://www.progenacell.com/

By: Charles Studios

View post:
Cell Therapy - Auto Immune Disease - Video

Recommendation and review posted by Bethany Smith

Cell Therapy - Body Approach
For More Information Visit: http://www.progenacell.com/

By: Charles Studios

See the article here:
Cell Therapy - Body Approach - Video

Recommendation and review posted by Bethany Smith

Cell Therapy - Lime Disease
For More Information Visit: http://www.progenacell.com/

By: Charles Studios

View post:
Cell Therapy - Lime Disease - Video

Recommendation and review posted by Bethany Smith

Cell Therapy - Managing Treatments
For More Information Visit: http://www.progenacell.com/

By: Charles Studios

The rest is here:
Cell Therapy - Managing Treatments - Video

Recommendation and review posted by Bethany Smith

PALO ALTO, Calif.--(BUSINESS WIRE)--

Open Monoclonal Technology, Inc. (OMT), a leader in genetic engineering of animals for discovery of human therapeutic antibodies, today announced expansion of its ongoing collaboration with CNA Development LLC, an affiliate of Janssen Pharmaceuticals, Inc. (Janssen).

Following a preliminary collaboration on OmniRat announced in December 2012, OMT has now granted Janssen licenses to use all its genetically engineered animals, OmniRat, OmniMouse and OmniFlic, for an unlimited number of targets and indications. Under the terms of the expanded agreement, Janssen will pay OMT annual platform access fees and success-based development and commercial milestone payments for each product derived from OMTs antibody platforms.

Dr. Roland Buelow, Founder and CEO of OMT, said: "Unlimited, triple-platform access provides OMTs partners with cost-efficient ability to create superior antibodies against some of the most challenging targets. OMT expects to see more and more partners taking such broad access, which will make OMT a profitable biotech company without need for further private or public funding.

OMT offers its collaborators both target-by-target and unlimited platform access. Target-by-target licensing allows the partners to use the technologies in a limited fashion and compare them to existing internal technologies, including humanization of animal-derived antibodies, optimization of display-derived antibodies, and alternative transgenic animal systems. Unlimited platform access provides a more cost-effective long term alternative and gives OMT and its partners more chances at discovery and development of clinically-commercially successful therapeutic antibodies.

Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for discovery of human therapeutic antibodies naturally optimized human antibodies.

OMT has created OmniRat, the industrys first fully human monoclonal antibody platform based on rats. It represents a novel and proprietary technology with unrestricted development options. OMT and Pfizer have demonstrated that OmniRat has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as a wild-type animals make rat antibodies (Journal of Immunology 2013 Feb 15; 190(4):1481-90).

OmniMouse is a transgenic mouse designed to complement OmniRat and further increase epitope coverage. Both animals deliver antibodies with great affinity, specificity, expression, solubility and stability, yet with low or no immunogenicity or need for lead optimization. OmniFlic is the industrys first engineered rat with a fixed light chain for development of human bispecific antibodies.

OMTs antibody platforms have broad freedom to operate and use technology protected by new patents and patent applications. They are available for licensing worldwide for all targets and indications and are presently partnered with Merck KGaA, Pfizer, WuXi AppTec and other biopharmaceutical companies.

Read more here:
Open Monoclonal Technology, Inc. Grants Unlimited Platform Access to CNA Development LLC, an Affiliate of Janssen ...

Recommendation and review posted by Bethany Smith

Public release date: 6-Oct-2013 [ | E-mail | Share ]

Contact: Kara Gavin kegavin@umich.edu 734-764-2220 University of Michigan Health System

ANN ARBOR, Mich. A global hunt for genes that influence heart disease risk has uncovered 157 changes in human DNA that alter the levels of cholesterol and other blood fats a discovery that could lead to new medications.

Each of the changes points to genes that can modify levels of cholesterol and other blood fats and are potential drug targets. Many of the changes point to genes not previously linked to blood fats, also called lipids. A surprising number of the variations were also associated with coronary artery disease, type 2 diabetes, obesity, and high blood pressure.

The research also reveals that triglycerides another type of blood lipid play a larger role in heart disease risk than previously thought.

The results, published in two new papers appearing simultaneously in the journal Nature Genetics, come from the Global Lipids Genetics Consortium -- a worldwide team of scientists who pooled genetic and clinical information from more than 188,000 people from many countries and heritages.

The analysis of the combined data was led by a team from the University of Michigan Medical School and School of Public Health. They used sophisticated computing and statistical techniques to search for genetic variations that modify blood lipid levels.

The results increase by more than a third the total number of genetic variants linked to blood lipids. All but one of the variants associated with blood lipids are near stretches of DNA that encode proteins.

"These results give us 62 new clues about lipid biology, and more places to look than we had before," says Cristen Willer, Ph.D., the lead author of one paper and an assistant professor of Internal Medicine, Human Genetics and Computational Medicine & Bioinformatics at the U-M Medical School. "Once we take the time to truly understand these clues, we'll have a better understanding of lipid biology and cardiovascular disease -- and potentially new targets for treatment."

But, cautions senior author and U-M School of Public Health Professor Gonalo Abecasis, Ph.D., it will take much further work to study the implicated genes and to find and test potential drugs that could target them. The consortium's "open science" approach will include publishing further detail online for other researchers to use freely toward this goal.

See original here:
Massive DNA study points to new heart drug targets and a key role for triglycerides

Recommendation and review posted by Bethany Smith